The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback